Renovare Therapeutics formally launched from stealth mode and announced its collaboration with University of Colorado (CU) Boulder, which was awarded a contract of up to $33.5 million in 2024 from the Advanced Research Projects Agency for Health (ARPA-H) and recently announced its advancement into the second phase of the award.
The funding, delivered under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, will support continued development of lead product candidates through IND-enabling and first-in-human Phase 1 safety studies. Renovare will collaborate with CU Boulder to advance these and other novel therapies toward commercialization.
Renovare was formed to further develop and commercialize product candidates from the portfolio developed under the NITRO program. These product candidates represent novel approaches to treat osteoarthritis that aim to be regenerative, potentially halting and reversing disease progression.
These technologies include controlled drug delivery systems and novel gene therapies to treat inflamed and degenerated joints via intra-articular injection or intravenous infusion, as well as advanced regenerative biomaterials for the treatment of cartilage and/or bone lesions delivered arthroscopically. Renovare boasts a pipeline of products that have the potential to be customized or combined to treat osteoarthritis patients at any stage of disease, with lead assets advancing towards IND-enabling studies in 2026.
Renovare Therapeutics formally launched from stealth mode and announced its collaboration with University of Colorado (CU) Boulder, which was awarded a contract of up to $33.5 million in 2024 from the Advanced Research Projects Agency for Health (ARPA-H) and recently announced its advancement into the second phase of the award.
The funding,...
Renovare Therapeutics formally launched from stealth mode and announced its collaboration with University of Colorado (CU) Boulder, which was awarded a contract of up to $33.5 million in 2024 from the Advanced Research Projects Agency for Health (ARPA-H) and recently announced its advancement into the second phase of the award.
The funding, delivered under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, will support continued development of lead product candidates through IND-enabling and first-in-human Phase 1 safety studies. Renovare will collaborate with CU Boulder to advance these and other novel therapies toward commercialization.
Renovare was formed to further develop and commercialize product candidates from the portfolio developed under the NITRO program. These product candidates represent novel approaches to treat osteoarthritis that aim to be regenerative, potentially halting and reversing disease progression.
These technologies include controlled drug delivery systems and novel gene therapies to treat inflamed and degenerated joints via intra-articular injection or intravenous infusion, as well as advanced regenerative biomaterials for the treatment of cartilage and/or bone lesions delivered arthroscopically. Renovare boasts a pipeline of products that have the potential to be customized or combined to treat osteoarthritis patients at any stage of disease, with lead assets advancing towards IND-enabling studies in 2026.
Copy to clipboard 
